数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Paulina Hill 女 Independent Director 44 未披露 未持股 2026-03-31
Carolyn Ng 女 Independent Director 42 未披露 未持股 2026-03-31
Valerie Odegard 女 Independent Director 49 43.71万美元 6.29 2026-03-31
Shelley Chu 女 Independent Director 56 未披露 未持股 2026-03-31
Gary D. Glick 男 Chief Executive Officer and Director and President 65 525.10万美元 125.79 2026-03-31
Ksenija Pavletic 女 Independent Director 54 未披露 未持股 2026-03-31
Nan Li 男 Independent Director 40 未披露 222.24 2026-03-31
Nia Tatsis 女 Independent Director 56 68.63万美元 未持股 2026-03-31
Jeffrey M. Leiden 男 Chair and Independent Director 70 153.64万美元 35.63 2026-03-31
Ian F. Smith 男 Independent Director 60 70.38万美元 24.61 2026-03-31
Timothy P. Walbert 男 Independent Director 59 59.32万美元 8.74 2026-03-31

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jolie M. Siegel 女 Executive Vice President and General Counsel and Secretary 50 未披露 未持股 2026-03-31
Gary D. Glick 男 Chief Executive Officer and Director and President 65 525.10万美元 125.79 2026-03-31
Jason Haas 男 Chief Financial Officer 59 148.01万美元 13.26 2026-03-31
Collin Todd 男 Senior Vice President, Strategy and Business Development 35 101.24万美元 6.95 2026-03-31
Natalie Dales 女 Chief of Research Operations and Portfolio Strategy 56 未披露 未持股 2026-03-31
Anthony Opipari 男 Executive Vice President, Translational Medicine and Interim Chief Medical Officer 61 未披露 未持股 2026-03-31

董事简历

中英对照 |  中文 |  英文
Paulina Hill

Paulina Hill自2017年6月以来一直担任我们的董事会成员。她自2015年以来一直担任Polaris Partners的负责人,2011年加入Polaris,担任其梦百合团队的助理。Hill博士担任Camp4Therapeutics的创始首席执行官。她任职于Kala Pharmaceuticals公司(上市制药公司)的董事会,以及Arsenal Medical公司、Faraday Pharmaceuticals公司、Kindex Pharmaceuticals公司、Camp4Therapeutics公司的私人公司董事会。Hill博士完成了她在麻省理工学院(Massachusetts Institute of Technology)化学工程系的博士后奖学金,在那里她致力于开发神经应用的新型生物材料支架和药物输送系统。她在东卡罗莱纳大学获得学士学位,并在维克森林大学医学院获得组织工程方向的分子医学博士学位。


Paulina Hill has served as a member of Odyssey Therapeutics, Inc.'s board of directors since June 2025. Since April 2022, Dr. Hill has served as a Partner at Sanofi Ventures. Prior to joining Sanofi, Dr. Hill was a Principal on the investment team at Omega Funds from January 2019 to December 2021. While there she incubated and served as the founding investor for Scorpion Therapeutics (acquired by Eli Lilly), and her investments included Arrakis Therapeutics, IFM Therapeutics, Synthekine and Vanqua Bio. Dr. Hill began her career with Polaris Partners, where she was on the investment team from January 2012 to October 2018. Dr. Hill currently serves on the boards of directors of several private companies including Avilar Therapeutics, Inc., NextPoint Therapeutics, Inc., Nuvig Therapeutics, Inc. and Tisento Therapeutics, Inc., and previously served on the board of directors of Normunity, Inc. She completed her postdoctoral fellowship in Robert Langer's lab in the Chemical Engineering Department at the Massachusetts Institute of Technology. Dr. Hill completed her Ph.D. in Molecular Medicine from Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry.
Paulina Hill自2017年6月以来一直担任我们的董事会成员。她自2015年以来一直担任Polaris Partners的负责人,2011年加入Polaris,担任其梦百合团队的助理。Hill博士担任Camp4Therapeutics的创始首席执行官。她任职于Kala Pharmaceuticals公司(上市制药公司)的董事会,以及Arsenal Medical公司、Faraday Pharmaceuticals公司、Kindex Pharmaceuticals公司、Camp4Therapeutics公司的私人公司董事会。Hill博士完成了她在麻省理工学院(Massachusetts Institute of Technology)化学工程系的博士后奖学金,在那里她致力于开发神经应用的新型生物材料支架和药物输送系统。她在东卡罗莱纳大学获得学士学位,并在维克森林大学医学院获得组织工程方向的分子医学博士学位。
Paulina Hill has served as a member of Odyssey Therapeutics, Inc.'s board of directors since June 2025. Since April 2022, Dr. Hill has served as a Partner at Sanofi Ventures. Prior to joining Sanofi, Dr. Hill was a Principal on the investment team at Omega Funds from January 2019 to December 2021. While there she incubated and served as the founding investor for Scorpion Therapeutics (acquired by Eli Lilly), and her investments included Arrakis Therapeutics, IFM Therapeutics, Synthekine and Vanqua Bio. Dr. Hill began her career with Polaris Partners, where she was on the investment team from January 2012 to October 2018. Dr. Hill currently serves on the boards of directors of several private companies including Avilar Therapeutics, Inc., NextPoint Therapeutics, Inc., Nuvig Therapeutics, Inc. and Tisento Therapeutics, Inc., and previously served on the board of directors of Normunity, Inc. She completed her postdoctoral fellowship in Robert Langer's lab in the Chemical Engineering Department at the Massachusetts Institute of Technology. Dr. Hill completed her Ph.D. in Molecular Medicine from Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry.
Carolyn Ng

Carolyn Ng自2018年以来一直担任我们的董事会成员。Ng博士是Vertex Ventures HC(一家全球风险投资公司)的负责人。吴博士目前在Obsidian Therapeutics,Inc.,Boundless Bio,Inc.,Twentyeight-Seven Therapeutics,Inc.和Nuvaira,Inc.的董事会任职。加入Vertex之前,Ng从2012年到2014年担任Deallus Consulting(一家专业生命科学咨询公司)制药战略顾问。Ng博士在新加坡国立大学癌症研究所(National University Cancer Institute of Singapore)肿瘤药学系开始她的职业生涯,她于2006年在那里工作。Ng博士拥有新加坡国立大学(National University of Singapore)综合科学与技术研究生院癌症分子生物学博士学位和新加坡国立大学(National University of Singapore)一级荣誉药学B.S.学位。


Carolyn Ng,has served as a member of Bicara Therapeutics Inc. board of directors since December 2023. Dr. Ng currently serves as is a Partner and Managing Director at TPG Life Sciences Innovations, or TPG, a global investment firm, based in San Francisco, where she leads investments into transformative companies in different therapeutic areas since October 2021. Prior to joining TPG, Dr. Ng was a Managing Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she joined in February 2015 and was promoted through various roles to be the co-Head of the investment team from June 2017 to September 2021. Dr. Ng currently serves on the board of directors of numerous private life sciences companies and previously served on the board of directors of several public companies, including Bicycle Therapeutics PLC (NASDAQ: BCYC), a biotechnology company, from June 2017 until August 2020, and Boundless Bio, Inc. (NASDAQ: BOLD), a clinical-stage oncology company, from June 2019 to September 2021. Dr. Ng holds a PhD in Cancer Molecular Biology from the National University of Singapore, where she was the recipient of the prestigious NGS, Integrative Sciences and Technology, PhD scholarship and holds a B.S. degree in Pharmacy with first class honors from the National University of Singapore.
Carolyn Ng自2018年以来一直担任我们的董事会成员。Ng博士是Vertex Ventures HC(一家全球风险投资公司)的负责人。吴博士目前在Obsidian Therapeutics,Inc.,Boundless Bio,Inc.,Twentyeight-Seven Therapeutics,Inc.和Nuvaira,Inc.的董事会任职。加入Vertex之前,Ng从2012年到2014年担任Deallus Consulting(一家专业生命科学咨询公司)制药战略顾问。Ng博士在新加坡国立大学癌症研究所(National University Cancer Institute of Singapore)肿瘤药学系开始她的职业生涯,她于2006年在那里工作。Ng博士拥有新加坡国立大学(National University of Singapore)综合科学与技术研究生院癌症分子生物学博士学位和新加坡国立大学(National University of Singapore)一级荣誉药学B.S.学位。
Carolyn Ng,has served as a member of Bicara Therapeutics Inc. board of directors since December 2023. Dr. Ng currently serves as is a Partner and Managing Director at TPG Life Sciences Innovations, or TPG, a global investment firm, based in San Francisco, where she leads investments into transformative companies in different therapeutic areas since October 2021. Prior to joining TPG, Dr. Ng was a Managing Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she joined in February 2015 and was promoted through various roles to be the co-Head of the investment team from June 2017 to September 2021. Dr. Ng currently serves on the board of directors of numerous private life sciences companies and previously served on the board of directors of several public companies, including Bicycle Therapeutics PLC (NASDAQ: BCYC), a biotechnology company, from June 2017 until August 2020, and Boundless Bio, Inc. (NASDAQ: BOLD), a clinical-stage oncology company, from June 2019 to September 2021. Dr. Ng holds a PhD in Cancer Molecular Biology from the National University of Singapore, where she was the recipient of the prestigious NGS, Integrative Sciences and Technology, PhD scholarship and holds a B.S. degree in Pharmacy with first class honors from the National University of Singapore.
Valerie Odegard

Valerie Odegard于2016年加入Silverback,自2020年9月起担任我们的总裁,自2018年10月起担任我们的首席科学官。此前,Odegard博士于2014年9月至2016年10月担任JunoTherapeutics,Inc.研究Vice President,负责发现,临床前开发和转化研究,从而将新型癌症免疫疗法推进到临床开发。此前,她曾担任Novo Nordisk公司和Trubion Pharmaceuticals公司的研究领导职务,在那里她曾监管肿瘤和炎症条件的疗法的发现和临床前开发。Odegard博士拥有维克森林大学(Wake Forest University)生物学学士学位和耶鲁大学(Yale University)免疫生物学博士学位。


Valerie Odegard has served as a member of Odyssey Therapeutics, Inc.'s board of directors since October 2021. Dr. Odegard has been involved in the discovery and development of drugs for autoimmune diseases and oncology for over 20 years. Dr. Odegard has served as the Chief Executive Officer of Dovetail Therapeutics, Inc. since October 2023 and as a director since May 2023. From October 2016 until September 2022, Dr. Odegard served in various roles with Silverback Therapeutics, Inc., including as Chief Scientific Officer starting in October 2018 and President starting in September 2020. Since October 2022, Dr. Odegard has also served as a venture partner at OrbiMed. Dr. Odegard holds a B.S. in biology from Wake Forest University and a Ph.D. in immunobiology from Yale University.
Valerie Odegard于2016年加入Silverback,自2020年9月起担任我们的总裁,自2018年10月起担任我们的首席科学官。此前,Odegard博士于2014年9月至2016年10月担任JunoTherapeutics,Inc.研究Vice President,负责发现,临床前开发和转化研究,从而将新型癌症免疫疗法推进到临床开发。此前,她曾担任Novo Nordisk公司和Trubion Pharmaceuticals公司的研究领导职务,在那里她曾监管肿瘤和炎症条件的疗法的发现和临床前开发。Odegard博士拥有维克森林大学(Wake Forest University)生物学学士学位和耶鲁大学(Yale University)免疫生物学博士学位。
Valerie Odegard has served as a member of Odyssey Therapeutics, Inc.'s board of directors since October 2021. Dr. Odegard has been involved in the discovery and development of drugs for autoimmune diseases and oncology for over 20 years. Dr. Odegard has served as the Chief Executive Officer of Dovetail Therapeutics, Inc. since October 2023 and as a director since May 2023. From October 2016 until September 2022, Dr. Odegard served in various roles with Silverback Therapeutics, Inc., including as Chief Scientific Officer starting in October 2018 and President starting in September 2020. Since October 2022, Dr. Odegard has also served as a venture partner at OrbiMed. Dr. Odegard holds a B.S. in biology from Wake Forest University and a Ph.D. in immunobiology from Yale University.
Shelley Chu

Shelley Chu自2021年8月起在我们的董事会任职。自2020年11月起,朱博士一直担任Lightspeed Venture Partners的合伙人。在加入Lightspeed之前,朱博士于2012年至2015年担任吉利德研发战略高级总监,领导所有治疗领域的研发战略以及免疫肿瘤学和HBV的业务发展。她曾在多家私营公司的董事会任职,包括Phathom Pharmaceuticals, Inc.、Enlaza Therapeutics,Inc.、Abata Therapeutics,Inc.、3T Biosciences,Inc.、Medikine,Inc.、Adanate,Inc.、Scorpion Therapeutics,Inc.、Tizona Therapeutics,Inc.被Gilead Sciences收购、Trishula Therapeutics,Inc.(与AbbVie合作)、SFJ Pharmaceuticals,Inc.、IFM Therapeutics,Inc.(被百时美施贵宝收购)、IFM TRE(被诺华收购)、IFM Due(与诺华合作)、IFM Quattro、Q32 Bio Inc.和VenatoRx Pharmaceuticals,Inc。朱博士拥有加州大学旧金山分校的生物化学和生物物理学医学博士和博士学位,以及普林斯顿大学的分子生物学学士学位,她是普林斯顿ASC的联合主席。她还是BioCentury科学顾问委员会的成员。


Shelley Chu has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2025. Since 2020, Dr. Chu has been a Partner of Lightspeed Venture Partners where she leads the Biotech practice and co heads the Healthcare Sector. She currently serves on the board of directors of Antares Therapeutics, Diagonal Therapeutics, Alpha 9 Oncology, Seismic Therapeutics, Triana Therapeutics, Enlaza Therapeutics, Protego BioPharma, and Zag Bio, and has previously served on the board of directors of private and public companies, including Scorpion Therapeutics (acquired by Eli Lilly & Co.), HilleVax (Nasdaq: HLVX), Tizona Therapeutics, Inc. (acquired by Gilead Sciences, Inc.), Trishula Therapeutics (partnered with AbbVie Inc.), IFM Therapeutics, LLC (acquired by Bristol Myers Squibb), IFM Tre (acquired by Novartis AG), IFM Due (acquired by Novartis AG), IFM Quattro, and SFJ Pharmaceuticals. Dr. Chu also led R&D strategy across all therapeutic areas as well as business development in immuno oncology and HBV at Gilead during the launch of their cure for HCV. Dr. Chu holds an M.D. and a Ph.D. in Biochemistry and Biophysics from the University of California at San Francisco and a B.A. in Molecular Biology from Princeton University, where she serves as Co Chair for Princeton ASC. She is also a member of the Scientific Advisory Board for BioCentury.
Shelley Chu自2021年8月起在我们的董事会任职。自2020年11月起,朱博士一直担任Lightspeed Venture Partners的合伙人。在加入Lightspeed之前,朱博士于2012年至2015年担任吉利德研发战略高级总监,领导所有治疗领域的研发战略以及免疫肿瘤学和HBV的业务发展。她曾在多家私营公司的董事会任职,包括Phathom Pharmaceuticals, Inc.、Enlaza Therapeutics,Inc.、Abata Therapeutics,Inc.、3T Biosciences,Inc.、Medikine,Inc.、Adanate,Inc.、Scorpion Therapeutics,Inc.、Tizona Therapeutics,Inc.被Gilead Sciences收购、Trishula Therapeutics,Inc.(与AbbVie合作)、SFJ Pharmaceuticals,Inc.、IFM Therapeutics,Inc.(被百时美施贵宝收购)、IFM TRE(被诺华收购)、IFM Due(与诺华合作)、IFM Quattro、Q32 Bio Inc.和VenatoRx Pharmaceuticals,Inc。朱博士拥有加州大学旧金山分校的生物化学和生物物理学医学博士和博士学位,以及普林斯顿大学的分子生物学学士学位,她是普林斯顿ASC的联合主席。她还是BioCentury科学顾问委员会的成员。
Shelley Chu has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2025. Since 2020, Dr. Chu has been a Partner of Lightspeed Venture Partners where she leads the Biotech practice and co heads the Healthcare Sector. She currently serves on the board of directors of Antares Therapeutics, Diagonal Therapeutics, Alpha 9 Oncology, Seismic Therapeutics, Triana Therapeutics, Enlaza Therapeutics, Protego BioPharma, and Zag Bio, and has previously served on the board of directors of private and public companies, including Scorpion Therapeutics (acquired by Eli Lilly & Co.), HilleVax (Nasdaq: HLVX), Tizona Therapeutics, Inc. (acquired by Gilead Sciences, Inc.), Trishula Therapeutics (partnered with AbbVie Inc.), IFM Therapeutics, LLC (acquired by Bristol Myers Squibb), IFM Tre (acquired by Novartis AG), IFM Due (acquired by Novartis AG), IFM Quattro, and SFJ Pharmaceuticals. Dr. Chu also led R&D strategy across all therapeutic areas as well as business development in immuno oncology and HBV at Gilead during the launch of their cure for HCV. Dr. Chu holds an M.D. and a Ph.D. in Biochemistry and Biophysics from the University of California at San Francisco and a B.A. in Molecular Biology from Princeton University, where she serves as Co Chair for Princeton ASC. She is also a member of the Scientific Advisory Board for BioCentury.
Gary D. Glick

Gary D. Glick,是一位化学家和连续生物技术企业家,在生物技术行业拥有超过15年的经验。他创立了几家成功的公司,包括IFM Therapeutics,LLC,即私营生物技术公司IFM。Glick博士自2019年12月起担任IFM执行主席,此前曾于2015年至2019年11月担任首席执行官。在Glick博士担任首席执行官期间,IFM推进了从构思到临床开发的三个项目,并执行了几项重大交易,迄今已产生7.5亿美元的收益。在实现各种里程碑的情况下,此类销售的收益可能会达到47亿美元以上。在2021年创立Odyssey之前,Glick博士于2020年2月与他人共同创立并推出了Scorpion Therapeutics,即Scorpion,在该公司的构想和建设中发挥了重要作用。在2020年2月至2021年2月担任首席执行官期间,Scorpion的员工人数增长至近50人,并通过两次融资筹集了2.7亿美元。2025年1月13日,公告称礼来与公司签订了一项最终协议,将以高达25亿美元的现金收购Scorpion。Glick博士还在其职业生涯早期创立了Lycera公司,担任首席科学官。格利克博士在哥伦比亚大学获得有机化学博士学位,并在哈佛大学完成了美国国立卫生研究院有机化学博士后研究金。


Gary D. Glick is Odyssey Therapeutics, Inc.'s founder and has served as Odyssey Therapeutics, Inc.'s President, Chief Executive Officer and a director since April 2021. Dr. Glick is a chemist and serial biotechnology entrepreneur with over 15 years of experience in the biotechnology industry. Dr. Glick has also served as the Executive Chairman of Charm Therapeutics Limited, or Charm, a London based biotechnology company focused on developing a new generation of menin inhibitors for acute myeloid leukemia, since January 2022, and as interim Chief Executive Officer since June 2025. While Dr. Glick works on a full time basis for Odyssey as Odyssey Therapeutics, Inc.'s Chief Executive Officer, he also devotes approximately 10 hours per week, on average, to his role at Charm, which time commitment is not materially different to what was required when he was Executive Chairman and not also interim Chief Executive Officer. In fulfilling his responsibilities to Charm, Dr. Glick seeks to leverage the time zone difference between London and Boston to complete as many of his responsibilities as possible for Charm during times that are outside of customary business hours in Boston. Dr. Glick has founded several successful companies, including IFM Therapeutics, LLC, or IFM, a private biotechnology company. Dr. Glick has served as Executive Chairman of IFM since December 2019 and previously served as Chief Executive Officer from 2015 to November 2019. During Dr. Glick's tenure as Chief Executive Officer, IFM progressed three programs from ideation to clinical development and executed several major transactions generating proceeds to date of $750 million. Subject to the achievement of various milestones, proceeds from those sales could reach more than $4.7 billion. Prior to founding Odyssey in 2021, Dr. Glick co founded and launched Scorpion Therapeutics, or Scorpion, in February 2020, where he played an instrumental role in the conception and building of the company. During his tenure as Chief Executive Officer from February 2020 to February 2021, Scorpion grew to nearly 50 employees and raised $270 million across two financings. In 2025, Eli Lilly and Company acquired Scorpion for up to $2.5 billion in cash. Dr. Glick also founded Lycera Corporation earlier in his career, serving as Chief Scientific Officer. Dr. Glick received his Ph.D. in organic chemistry from Columbia University and completed an NIH postdoctoral fellowship in organic chemistry at Harvard University.
Gary D. Glick,是一位化学家和连续生物技术企业家,在生物技术行业拥有超过15年的经验。他创立了几家成功的公司,包括IFM Therapeutics,LLC,即私营生物技术公司IFM。Glick博士自2019年12月起担任IFM执行主席,此前曾于2015年至2019年11月担任首席执行官。在Glick博士担任首席执行官期间,IFM推进了从构思到临床开发的三个项目,并执行了几项重大交易,迄今已产生7.5亿美元的收益。在实现各种里程碑的情况下,此类销售的收益可能会达到47亿美元以上。在2021年创立Odyssey之前,Glick博士于2020年2月与他人共同创立并推出了Scorpion Therapeutics,即Scorpion,在该公司的构想和建设中发挥了重要作用。在2020年2月至2021年2月担任首席执行官期间,Scorpion的员工人数增长至近50人,并通过两次融资筹集了2.7亿美元。2025年1月13日,公告称礼来与公司签订了一项最终协议,将以高达25亿美元的现金收购Scorpion。Glick博士还在其职业生涯早期创立了Lycera公司,担任首席科学官。格利克博士在哥伦比亚大学获得有机化学博士学位,并在哈佛大学完成了美国国立卫生研究院有机化学博士后研究金。
Gary D. Glick is Odyssey Therapeutics, Inc.'s founder and has served as Odyssey Therapeutics, Inc.'s President, Chief Executive Officer and a director since April 2021. Dr. Glick is a chemist and serial biotechnology entrepreneur with over 15 years of experience in the biotechnology industry. Dr. Glick has also served as the Executive Chairman of Charm Therapeutics Limited, or Charm, a London based biotechnology company focused on developing a new generation of menin inhibitors for acute myeloid leukemia, since January 2022, and as interim Chief Executive Officer since June 2025. While Dr. Glick works on a full time basis for Odyssey as Odyssey Therapeutics, Inc.'s Chief Executive Officer, he also devotes approximately 10 hours per week, on average, to his role at Charm, which time commitment is not materially different to what was required when he was Executive Chairman and not also interim Chief Executive Officer. In fulfilling his responsibilities to Charm, Dr. Glick seeks to leverage the time zone difference between London and Boston to complete as many of his responsibilities as possible for Charm during times that are outside of customary business hours in Boston. Dr. Glick has founded several successful companies, including IFM Therapeutics, LLC, or IFM, a private biotechnology company. Dr. Glick has served as Executive Chairman of IFM since December 2019 and previously served as Chief Executive Officer from 2015 to November 2019. During Dr. Glick's tenure as Chief Executive Officer, IFM progressed three programs from ideation to clinical development and executed several major transactions generating proceeds to date of $750 million. Subject to the achievement of various milestones, proceeds from those sales could reach more than $4.7 billion. Prior to founding Odyssey in 2021, Dr. Glick co founded and launched Scorpion Therapeutics, or Scorpion, in February 2020, where he played an instrumental role in the conception and building of the company. During his tenure as Chief Executive Officer from February 2020 to February 2021, Scorpion grew to nearly 50 employees and raised $270 million across two financings. In 2025, Eli Lilly and Company acquired Scorpion for up to $2.5 billion in cash. Dr. Glick also founded Lycera Corporation earlier in his career, serving as Chief Scientific Officer. Dr. Glick received his Ph.D. in organic chemistry from Columbia University and completed an NIH postdoctoral fellowship in organic chemistry at Harvard University.
Ksenija Pavletic

Ksenija Pavletic自2025年8月起担任Odyssey Therapeutics,Inc.董事会成员。自2025年10月起,Pavletic女士担任Jeito Capital的普通合伙人和首席商务官,Jeito Capital是一家全球领先的投资公司,专注于打造变革性生物制药公司。她作为运营投资者和首席商务官加入了Jeito的投资团队,并于2024年晋升为合伙人,然后于2025年晋升为普通合伙人。她是一位充满活力的高管,在制药和生物技术领域拥有超过25年的全球经验。她是投资策略和医疗保健公司放大方面的专家,在筹资、并购、公司放大、商业组织建立、产品发布和市场准入方面拥有成功的业绩记录。作为Jeito创始团队的一员,Pavletic女士自公司成立以来为公司的发展做出了重大贡献。Pavletic女士还自2022年10月起担任Advesya的首席执行官,该公司是一家开创性和变革性的生物技术公司,致力于为难以治疗的癌症开发疗法。在加入Jeito之前,Pavletic女士于2015年7月至2022年1月担任总部位于瑞士的生殖健康制药公司PregLem SA的首席执行官,在那里她领导了该公司的快速扩张,包括成功退出。在加入PreGLem之前,她曾在雪兰诺(当时的默沙东 Serono)工作了十一年,担任过多个区域和全球业务、销售和营销职位。Pavletic女士目前担任多家私营公司的董事会成员,包括Azafaros B.V.、Callio Therapeutics和ReproNovo。此前,Pavletic女士于2020年5月至2024年11月期间担任MaxiVAX SA(现为Release Therapeutics)的董事。她拥有萨格勒布大学生物技术硕士学位和韦伯斯特大学美国商学院工商管理硕士学位。


Ksenija Pavletic has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2025. Since October 2025, Ms. Pavletic has served as General Partner and Chief Commercial Officer at Jeito Capital, a leading global investment company focused on building transformative biopharma companies. She joined the investment team at Jeito as Operational Investor and Chief Commercial Officer and was promoted to Partner in 2024, then General Partner in 2025. She is a dynamic executive with more than 25 years of global experience in the pharmaceutical and biotechnology sectors. She is an expert in both investment strategies and healthcare companies scaleups with a successful track record in fund raising, M&A, company scaleups, commercial organization build ups, product launches and market access. As part of Jeito's founding team, Ms. Pavletic has significantly contributed to the firm's development since its inception. Ms. Pavletic has also served as Chief Executive Officer of Advesya since October 2022, a pioneering and transformative biotechnology company developing therapies for difficult to treat cancers. Prior to joining Jeito, Ms. Pavletic was CEO of Swiss based, reproductive health pharma company PregLem SA from July 2015 to January 2022, where she led the company's rapid expansion including its successful exit. Before PregLem, she worked for eleven years with Serono (then Merck Serono) in various regional and global business, sales and marketing positions. Ms. Pavletic currently serves on the boards of several private companies including Azafaros B.V., Callio Therapeutics and ReproNovo. Previously, Ms. Pavletic was a director at MaxiVAX SA (now Release Therapeutics) from May 2020 to November 2024. She holds a M.Sc. in biotechnology from University of Zagreb and M.B.A. from American Graduate School of Business at Webster University.
Ksenija Pavletic自2025年8月起担任Odyssey Therapeutics,Inc.董事会成员。自2025年10月起,Pavletic女士担任Jeito Capital的普通合伙人和首席商务官,Jeito Capital是一家全球领先的投资公司,专注于打造变革性生物制药公司。她作为运营投资者和首席商务官加入了Jeito的投资团队,并于2024年晋升为合伙人,然后于2025年晋升为普通合伙人。她是一位充满活力的高管,在制药和生物技术领域拥有超过25年的全球经验。她是投资策略和医疗保健公司放大方面的专家,在筹资、并购、公司放大、商业组织建立、产品发布和市场准入方面拥有成功的业绩记录。作为Jeito创始团队的一员,Pavletic女士自公司成立以来为公司的发展做出了重大贡献。Pavletic女士还自2022年10月起担任Advesya的首席执行官,该公司是一家开创性和变革性的生物技术公司,致力于为难以治疗的癌症开发疗法。在加入Jeito之前,Pavletic女士于2015年7月至2022年1月担任总部位于瑞士的生殖健康制药公司PregLem SA的首席执行官,在那里她领导了该公司的快速扩张,包括成功退出。在加入PreGLem之前,她曾在雪兰诺(当时的默沙东 Serono)工作了十一年,担任过多个区域和全球业务、销售和营销职位。Pavletic女士目前担任多家私营公司的董事会成员,包括Azafaros B.V.、Callio Therapeutics和ReproNovo。此前,Pavletic女士于2020年5月至2024年11月期间担任MaxiVAX SA(现为Release Therapeutics)的董事。她拥有萨格勒布大学生物技术硕士学位和韦伯斯特大学美国商学院工商管理硕士学位。
Ksenija Pavletic has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2025. Since October 2025, Ms. Pavletic has served as General Partner and Chief Commercial Officer at Jeito Capital, a leading global investment company focused on building transformative biopharma companies. She joined the investment team at Jeito as Operational Investor and Chief Commercial Officer and was promoted to Partner in 2024, then General Partner in 2025. She is a dynamic executive with more than 25 years of global experience in the pharmaceutical and biotechnology sectors. She is an expert in both investment strategies and healthcare companies scaleups with a successful track record in fund raising, M&A, company scaleups, commercial organization build ups, product launches and market access. As part of Jeito's founding team, Ms. Pavletic has significantly contributed to the firm's development since its inception. Ms. Pavletic has also served as Chief Executive Officer of Advesya since October 2022, a pioneering and transformative biotechnology company developing therapies for difficult to treat cancers. Prior to joining Jeito, Ms. Pavletic was CEO of Swiss based, reproductive health pharma company PregLem SA from July 2015 to January 2022, where she led the company's rapid expansion including its successful exit. Before PregLem, she worked for eleven years with Serono (then Merck Serono) in various regional and global business, sales and marketing positions. Ms. Pavletic currently serves on the boards of several private companies including Azafaros B.V., Callio Therapeutics and ReproNovo. Previously, Ms. Pavletic was a director at MaxiVAX SA (now Release Therapeutics) from May 2020 to November 2024. She holds a M.Sc. in biotechnology from University of Zagreb and M.B.A. from American Graduate School of Business at Webster University.
Nan Li

李楠自2025年6月起担任Odyssey Therapeutics,Inc.董事会成员。李先生自2022年4月起担任Dimension Capital的联合创始人和管理合伙人,Dimension Capital是一家技术与生命科学接口的多阶段投资公司。Dimension与有远见的创始人合作,他们在治疗、诊断、软件应用、自动化系统和技术支持服务领域开展工作。李先生对包括计算机视觉、AI/ML、NLP、机器人和自动化系统在内的尖端技术的发展感兴趣。在创立Dimension Capital之前,李先生于2015年3月至2022年4月担任Obvious Ventures的董事总经理,在那里他与公司合作,从早期公司组建到通过公开市场开发前沿技术。这包括Automata Technologies、Aspect Biosystems Ltd.、Dexterity,Inc.、Dyno Therapeutics,Inc.、Iterative Scopes,Inc. d/b/a Iterative Health、Planet Labs PBC(NYSE:PL)、Recursion Pharma(纳斯达克:RXRX)和SwiftScale Biologics。李先生目前在Aspect Biosystems Ltd.、Automata Technologies、FiveoneFour Labs Inc.和Tamarind Bio,Inc.的董事会任职。此外,李先生此前还曾在Anagenix Ltd.、Darwin Inc.、Dexterity,Inc.、Gandeeva Therapeutics,Inc.、Inato,Inc.、Iterative Scopes,Inc. d/b/a Iterative Health、LabGenius Therapeutics、Octave Health Group Inc.和The Aifleet Inc.的董事会任职。李先生拥有密歇根大学计算机科学学士学位。他还曾在斯坦福大学担任人工智能和风险投资方面的讲师。


Nan Li has served as a member of Odyssey Therapeutics, Inc.'s board of directors since June 2025. Mr. Li has served as Co Founder and Managing Partner of Dimension Capital since April 2022, a multistage investment firm at the interface of technology and life science. Dimension partners with visionary founders working across therapeutics, diagnostics, software applications, automation systems and tech enabled services. Mr. Li is interested in the development of cutting edge technologies including computer vision, AI/ML, NLP, robotics and automation systems. Prior to founding Dimension Capital, Mr. Li was a Managing Director at Obvious Ventures from March 2015 to April 2022, where he worked with companies developing frontier technologies from early company formation through public markets. This includes Automata Technologies, Aspect Biosystems Ltd., Dexterity, Inc., Dyno Therapeutics, Inc., Iterative Scopes, Inc. d/b/a Iterative Health, Planet Labs PBC (NYSE: PL), Recursion Pharma (Nasdaq: RXRX) and SwiftScale Biologics. Mr. Li currently serves on the boards of directors of Aspect Biosystems Ltd., Automata Technologies, Fiveonefour Labs Inc. and Tamarind Bio, Inc. In addition, Mr. Li previously served on the boards of directors of Anagenix Ltd., Darwin Inc., Dexterity, Inc., Gandeeva Therapeutics, Inc., Inato, Inc., Iterative Scopes, Inc. d/b/a Iterative Health, LabGenius Therapeutics, Octave Health Group Inc. and The Aifleet Inc. Mr. Li holds a BSE in Computer Science from the University of Michigan. He has also been a Lecturer at Stanford University on artificial intelligence and venture capital.
李楠自2025年6月起担任Odyssey Therapeutics,Inc.董事会成员。李先生自2022年4月起担任Dimension Capital的联合创始人和管理合伙人,Dimension Capital是一家技术与生命科学接口的多阶段投资公司。Dimension与有远见的创始人合作,他们在治疗、诊断、软件应用、自动化系统和技术支持服务领域开展工作。李先生对包括计算机视觉、AI/ML、NLP、机器人和自动化系统在内的尖端技术的发展感兴趣。在创立Dimension Capital之前,李先生于2015年3月至2022年4月担任Obvious Ventures的董事总经理,在那里他与公司合作,从早期公司组建到通过公开市场开发前沿技术。这包括Automata Technologies、Aspect Biosystems Ltd.、Dexterity,Inc.、Dyno Therapeutics,Inc.、Iterative Scopes,Inc. d/b/a Iterative Health、Planet Labs PBC(NYSE:PL)、Recursion Pharma(纳斯达克:RXRX)和SwiftScale Biologics。李先生目前在Aspect Biosystems Ltd.、Automata Technologies、FiveoneFour Labs Inc.和Tamarind Bio,Inc.的董事会任职。此外,李先生此前还曾在Anagenix Ltd.、Darwin Inc.、Dexterity,Inc.、Gandeeva Therapeutics,Inc.、Inato,Inc.、Iterative Scopes,Inc. d/b/a Iterative Health、LabGenius Therapeutics、Octave Health Group Inc.和The Aifleet Inc.的董事会任职。李先生拥有密歇根大学计算机科学学士学位。他还曾在斯坦福大学担任人工智能和风险投资方面的讲师。
Nan Li has served as a member of Odyssey Therapeutics, Inc.'s board of directors since June 2025. Mr. Li has served as Co Founder and Managing Partner of Dimension Capital since April 2022, a multistage investment firm at the interface of technology and life science. Dimension partners with visionary founders working across therapeutics, diagnostics, software applications, automation systems and tech enabled services. Mr. Li is interested in the development of cutting edge technologies including computer vision, AI/ML, NLP, robotics and automation systems. Prior to founding Dimension Capital, Mr. Li was a Managing Director at Obvious Ventures from March 2015 to April 2022, where he worked with companies developing frontier technologies from early company formation through public markets. This includes Automata Technologies, Aspect Biosystems Ltd., Dexterity, Inc., Dyno Therapeutics, Inc., Iterative Scopes, Inc. d/b/a Iterative Health, Planet Labs PBC (NYSE: PL), Recursion Pharma (Nasdaq: RXRX) and SwiftScale Biologics. Mr. Li currently serves on the boards of directors of Aspect Biosystems Ltd., Automata Technologies, Fiveonefour Labs Inc. and Tamarind Bio, Inc. In addition, Mr. Li previously served on the boards of directors of Anagenix Ltd., Darwin Inc., Dexterity, Inc., Gandeeva Therapeutics, Inc., Inato, Inc., Iterative Scopes, Inc. d/b/a Iterative Health, LabGenius Therapeutics, Octave Health Group Inc. and The Aifleet Inc. Mr. Li holds a BSE in Computer Science from the University of Michigan. He has also been a Lecturer at Stanford University on artificial intelligence and venture capital.
Nia Tatsis

Nia Tatsis自2025年9月起担任Odyssey Therapeutics,Inc.董事会成员。Tatsis博士目前是福泰制药的执行副总裁、首席法规和质量官。她于2017年加入福泰制药,担任监管主管,并于2020年被任命为首席监管和质量官。在加入福泰制药之前,Dr. Tatsis在赛诺菲、辉瑞、惠氏等制药公司担任的职务越来越重要。Tatsis博士于2024年至2025年期间担任Verve Therapeutics公司的董事会成员,并担任新英格兰国际学会领导委员会成员。此前,她曾在Wistar研究所担任免疫学和疫苗开发方面的参谋科学家和研究员。Tatsis博士在佛蒙特大学获得细胞和分子生物学博士学位,并在托马斯杰斐逊大学完成了免疫学博士后研究奖学金。她拥有天普大学生物学学士学位。


Nia Tatsis has served as a member of Odyssey Therapeutics, Inc.'s board of directors since September 2025. Dr. Tatsis is currently the Executive Vice President, Chief Regulatory and Quality Officer of Vertex. She joined Vertex in 2017 as Head of Regulatory and was appointed as Chief Regulatory and Quality Officer in 2020. Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies including Sanofi, Pfizer, and Wyeth. Dr. Tatsis has served as a member of the board of directors of Verve Therapeutics, Inc. from 2024 to 2025 and as a member of the leadership council of the International Institute of New England. Previously, she served as a staff scientist and research fellow in immunology and vaccine development at the Wistar Institute. Dr. Tatsis received her Ph.D. in cell and molecular biology from the University of Vermont and completed a postdoctoral research fellowship in immunology at Thomas Jefferson University. She holds a B.S. in biology from Temple University.
Nia Tatsis自2025年9月起担任Odyssey Therapeutics,Inc.董事会成员。Tatsis博士目前是福泰制药的执行副总裁、首席法规和质量官。她于2017年加入福泰制药,担任监管主管,并于2020年被任命为首席监管和质量官。在加入福泰制药之前,Dr. Tatsis在赛诺菲、辉瑞、惠氏等制药公司担任的职务越来越重要。Tatsis博士于2024年至2025年期间担任Verve Therapeutics公司的董事会成员,并担任新英格兰国际学会领导委员会成员。此前,她曾在Wistar研究所担任免疫学和疫苗开发方面的参谋科学家和研究员。Tatsis博士在佛蒙特大学获得细胞和分子生物学博士学位,并在托马斯杰斐逊大学完成了免疫学博士后研究奖学金。她拥有天普大学生物学学士学位。
Nia Tatsis has served as a member of Odyssey Therapeutics, Inc.'s board of directors since September 2025. Dr. Tatsis is currently the Executive Vice President, Chief Regulatory and Quality Officer of Vertex. She joined Vertex in 2017 as Head of Regulatory and was appointed as Chief Regulatory and Quality Officer in 2020. Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies including Sanofi, Pfizer, and Wyeth. Dr. Tatsis has served as a member of the board of directors of Verve Therapeutics, Inc. from 2024 to 2025 and as a member of the leadership council of the International Institute of New England. Previously, she served as a staff scientist and research fellow in immunology and vaccine development at the Wistar Institute. Dr. Tatsis received her Ph.D. in cell and molecular biology from the University of Vermont and completed a postdoctoral research fellowship in immunology at Thomas Jefferson University. She holds a B.S. in biology from Temple University.
Jeffrey M. Leiden

Jeffrey M. Leiden是执行主席,他于2020年4月起担任该职位。2012年至2020年3月,他担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁。2009年7月至今担任Vertex Pharmaceuticals Incorporated董事会成员,2012年5月至今担任Vertex Pharmaceuticals Incorporated董事会主席,并于2010年10月至2011年12月担任Vertex Pharmaceuticals Incorporated首席独立董事。Leiden博士于2006年至2012年1月期间担任生命科学风险投资公司Clarus风险投资公司的董事总经理。Leiden博士曾于2001年至2006年担任Pharmaceuticals Products Group 雅培的总裁兼首席运营官,并且是雅培的董事会成员。从1987年到2000年,Leiden博士担任过多个学术职务,包括芝加哥大学罗森医学和病理学教授和心脏病学主任兼心血管研究所所长、哈佛大学公共卫生学院Elkan R. Blout生物科学教授和哈佛医学院医学教授。他是美国艺术与科学院和美国国家科学院医学研究所的当选成员。Leiden博士自2015年起担任私营保险公司马萨诸塞州共同人寿保险公司的董事会成员。Leiden博士自2022年起担任私营生物技术公司Odyssey Therapeutics的董事会执行主席,并自2021年起担任私营医疗保健技术公司Casana的董事会主席。Leiden博士曾于2006年至2012年1月担任Shire PLC的董事和董事会非执行副主席,于2014年12月至2019年5月担任奎斯特诊疗的董事,并于2021年4月至2022年12月担任Revolution Healthcare Acquisition Corp.的董事长。Leiden博士在芝加哥大学获得了医学博士、博士和学士学位。


Jeffrey M. Leiden has served as Chair of Odyssey Therapeutics, Inc.'s board of directors and as a member of Odyssey Therapeutics, Inc.'s board of directors since March 2022. Dr. Leiden has served as the Executive Chairman of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), or Vertex, since April 2020, after serving as a director since July 2009. Dr. Leiden previously served as President, Chief Executive Officer and Chairman of Vertex from 2012 through March 2020. Prior to joining Vertex, Dr. Leiden served as Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2007 to 2012 and as President, Chief Operating Officer of Abbott Laboratories from 2000 until 2005. Dr. Leiden is a physician and scientist who has dedicated his career to improving the lives of people with serious diseases. While serving as Chief Executive Officer of Vertex, the company also built a robust pipeline of drug candidates in specialty markets, including pain, sickle cell disease and type 1 diabetes, and entered into important collaborations, like with CRISPR Therapeutics AG, which led to the discovery and development of the first CRISPR/Cas9 gene editing therapy, CASGEVY, approved for two human genetic diseases, sickle cell disease and beta thalassemia. Dr. Leiden is the lead director of Massachusetts Mutual Life Insurance Company, and the Chairman of the Board of Casana Care, Inc. and previously served on the board of directors of Shire plc, Millennium Pharmaceuticals, Inc. and Quest Diagnostics Incorporated (NYSE: DGX). Dr. Leiden received his B.A. in biological sciences, his Ph.D. in virology and his M.D. from the University of Chicago.
Jeffrey M. Leiden是执行主席,他于2020年4月起担任该职位。2012年至2020年3月,他担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁。2009年7月至今担任Vertex Pharmaceuticals Incorporated董事会成员,2012年5月至今担任Vertex Pharmaceuticals Incorporated董事会主席,并于2010年10月至2011年12月担任Vertex Pharmaceuticals Incorporated首席独立董事。Leiden博士于2006年至2012年1月期间担任生命科学风险投资公司Clarus风险投资公司的董事总经理。Leiden博士曾于2001年至2006年担任Pharmaceuticals Products Group 雅培的总裁兼首席运营官,并且是雅培的董事会成员。从1987年到2000年,Leiden博士担任过多个学术职务,包括芝加哥大学罗森医学和病理学教授和心脏病学主任兼心血管研究所所长、哈佛大学公共卫生学院Elkan R. Blout生物科学教授和哈佛医学院医学教授。他是美国艺术与科学院和美国国家科学院医学研究所的当选成员。Leiden博士自2015年起担任私营保险公司马萨诸塞州共同人寿保险公司的董事会成员。Leiden博士自2022年起担任私营生物技术公司Odyssey Therapeutics的董事会执行主席,并自2021年起担任私营医疗保健技术公司Casana的董事会主席。Leiden博士曾于2006年至2012年1月担任Shire PLC的董事和董事会非执行副主席,于2014年12月至2019年5月担任奎斯特诊疗的董事,并于2021年4月至2022年12月担任Revolution Healthcare Acquisition Corp.的董事长。Leiden博士在芝加哥大学获得了医学博士、博士和学士学位。
Jeffrey M. Leiden has served as Chair of Odyssey Therapeutics, Inc.'s board of directors and as a member of Odyssey Therapeutics, Inc.'s board of directors since March 2022. Dr. Leiden has served as the Executive Chairman of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), or Vertex, since April 2020, after serving as a director since July 2009. Dr. Leiden previously served as President, Chief Executive Officer and Chairman of Vertex from 2012 through March 2020. Prior to joining Vertex, Dr. Leiden served as Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2007 to 2012 and as President, Chief Operating Officer of Abbott Laboratories from 2000 until 2005. Dr. Leiden is a physician and scientist who has dedicated his career to improving the lives of people with serious diseases. While serving as Chief Executive Officer of Vertex, the company also built a robust pipeline of drug candidates in specialty markets, including pain, sickle cell disease and type 1 diabetes, and entered into important collaborations, like with CRISPR Therapeutics AG, which led to the discovery and development of the first CRISPR/Cas9 gene editing therapy, CASGEVY, approved for two human genetic diseases, sickle cell disease and beta thalassemia. Dr. Leiden is the lead director of Massachusetts Mutual Life Insurance Company, and the Chairman of the Board of Casana Care, Inc. and previously served on the board of directors of Shire plc, Millennium Pharmaceuticals, Inc. and Quest Diagnostics Incorporated (NYSE: DGX). Dr. Leiden received his B.A. in biological sciences, his Ph.D. in virology and his M.D. from the University of Chicago.
Ian F. Smith

Ian F. Smith,是一位经验丰富的领导者,拥有30多年的金融和运营经验。Smith先生目前担任Rivus Pharmaceutical Inc.的董事会主席,他自2023年11月以来一直担任该职位。Smith先生还担任贝恩资本生命科学公司的高级顾问(自2021年1月起担任该职位),以及自2020年6月起担任Solid Biosciences Inc.(纳斯达克:SLDB)董事会执行主席。他还自2021年4月起担任Foghorn Therapeutics Inc.(纳斯达克:FHTX)的董事会成员,并自2023年9月起担任Stoke Therapeutics, Inc.(纳斯达克:STOK)的董事会成员。在担任现任职务之前,Smith先生曾于2019年7月至2022年9月担任私营生物技术公司Viacyte的董事会执行主席。Smith先生此前曾于2001年至2019年1月在福泰制药担任过多个职务,包括首席财务官和首席运营官。在加入福泰制药之前,Smith先生是会计师事务所Ernst & Young LLP的合伙人,为私营和上市公司提供服务,包括生物技术公司。Smith先生还担任多家私营生物技术公司的董事会成员,并提供咨询服务。


Ian F. Smith has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2024 and prior to that as a consultant. Mr. Smith is an experienced leader with more than 30 years of finance and operating experience. Mr. Smith has served as Chief Executive Officer of Stoke Therapeutics, Inc. (Nasdaq: STOK) since October 2025 and a member of the board of directors since 2023, and previously served as Interim Chief Executive Officer from March 2025 to October 2025. In addition, Mr. Smith is the Chair of the board of directors for Rivus Pharmaceutical Inc., a position he has held since November 2023. Mr. Smith also serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021, and as Executive Chair of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB), which position he has held since June 2020. He has also served as a member of the board of directors of Foghorn Therapeutics Inc. (Nasdaq: FHTX) since April 2021. Prior to his current roles, Mr. Smith served as Executive Chair of the board of directors of Viacyte, a private biotechnology company, from July 2019 to September 2022. Mr. Smith previously served in various roles at Vertex from 2001 until January 2019, including as the Chief Financial Officer and Chief Operating Officer. Prior to joining Vertex, Mr. Smith was a partner of the accounting firm Ernst & Young LLP, serving private and public companies, including biotechnology companies. Mr. Smith also serves on the boards of a number of private biotechnology companies and provides advisory services. Mr. Smith holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).
Ian F. Smith,是一位经验丰富的领导者,拥有30多年的金融和运营经验。Smith先生目前担任Rivus Pharmaceutical Inc.的董事会主席,他自2023年11月以来一直担任该职位。Smith先生还担任贝恩资本生命科学公司的高级顾问(自2021年1月起担任该职位),以及自2020年6月起担任Solid Biosciences Inc.(纳斯达克:SLDB)董事会执行主席。他还自2021年4月起担任Foghorn Therapeutics Inc.(纳斯达克:FHTX)的董事会成员,并自2023年9月起担任Stoke Therapeutics, Inc.(纳斯达克:STOK)的董事会成员。在担任现任职务之前,Smith先生曾于2019年7月至2022年9月担任私营生物技术公司Viacyte的董事会执行主席。Smith先生此前曾于2001年至2019年1月在福泰制药担任过多个职务,包括首席财务官和首席运营官。在加入福泰制药之前,Smith先生是会计师事务所Ernst & Young LLP的合伙人,为私营和上市公司提供服务,包括生物技术公司。Smith先生还担任多家私营生物技术公司的董事会成员,并提供咨询服务。
Ian F. Smith has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2024 and prior to that as a consultant. Mr. Smith is an experienced leader with more than 30 years of finance and operating experience. Mr. Smith has served as Chief Executive Officer of Stoke Therapeutics, Inc. (Nasdaq: STOK) since October 2025 and a member of the board of directors since 2023, and previously served as Interim Chief Executive Officer from March 2025 to October 2025. In addition, Mr. Smith is the Chair of the board of directors for Rivus Pharmaceutical Inc., a position he has held since November 2023. Mr. Smith also serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021, and as Executive Chair of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB), which position he has held since June 2020. He has also served as a member of the board of directors of Foghorn Therapeutics Inc. (Nasdaq: FHTX) since April 2021. Prior to his current roles, Mr. Smith served as Executive Chair of the board of directors of Viacyte, a private biotechnology company, from July 2019 to September 2022. Mr. Smith previously served in various roles at Vertex from 2001 until January 2019, including as the Chief Financial Officer and Chief Operating Officer. Prior to joining Vertex, Mr. Smith was a partner of the accounting firm Ernst & Young LLP, serving private and public companies, including biotechnology companies. Mr. Smith also serves on the boards of a number of private biotechnology companies and provides advisory services. Mr. Smith holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).
Timothy P. Walbert

Timothy P. Walbert,自2010年公司成立起任公司的董事会主席,总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月,他是IDM Pharma, Inc.的总裁、董事兼首席执行官;公司是一家生物制药公司,于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月,他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月,他是Immunology的区域副总裁兼总经理,在此他领导HUMIRA的全球发展——于2013年超过110亿美元;且是Abbott全球心血管战略执行副总裁,该组织是一家医疗保健公司,现为AbbVie。1998年4月至2001年6月,他是Celebrex North America的董事,以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年,他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation (纳斯达克: XOMA) 、Raptor Pharmaceutical Corp. (纳斯达克: RPTP)、Egalet Corporation (纳斯达克: EGLT)、生物技术工业组织 (BIO)、伊利诺斯州生物技术工业组织 (iBIO)、 ChicagoNEXT、 a World Business Chicago (WBC) led council of technology leaders ,以及芝加哥关节炎基金会(the Greater Chicago Arthritis Foundation)的董事会任职。2013年,他被任命为 伊利诺斯州创新委员会(the Illinois Innovation Council)的主管人员。


Timothy P. Walbert has served as Chairman of Latigo Biotherapeutics, Inc.'s board of directors since October 2024. Since October 2023, Mr. Walbert has served as a senior advisor to Amgen Inc., a publicly held biotechnology company. Previously, Mr. Walbert was Chairman, President and Chief Executive Officer of Horizon Therapeutics Public Ltd Co (Horizon), a biotechnology company (acquired by Amgen), from June 2008 to October 2023. Prior to Horizon, he served as President, Chief Executive Officer and a member of the board of directors of IDM Pharma Inc., a biotechnology company (acquired by Takeda Pharmaceuticals). Prior to that, Mr. Walbert served as Executive Vice President, Commercial Operations at NeoPharm Inc., a publicly held biotechnology company. Mr. Walbert has served on the board of directors of multiple publicly held biotechnology companies, including Century Therapeutics, Inc. since September 2022, Mirum Pharmaceuticals, Inc. since April 2023, Sagimet Biosciences Inc. since March 2024, and BioMarin Pharmaceutical Inc. since February 2025, as well as Cour Pharmaceuticals Development Co., Inc. since June 2024, Odyssey Therapeutics, Inc. since October 2024, and Catalent, Inc. since February 2025 and Crystalys Therapeutics, Inc. since February 2026. He previously served on the board of directors of Aurinia Pharmaceuticals Inc., a publicly held pharmaceutical company, from 2020 to 2022, Exicure, Inc., a publicly held biotechnology company, from 2019 to 2022, Assertio Holdings, Inc., a publicly held biopharma company, from 2014 to 2020, Raptor Pharmaceutical Corp., a publicly held biotechnology company, from 2010 to 2014, XOMA Corporation, a publicly held biotechnology company, from 2011 to 2017, and Sucampo Pharmaceuticals Inc., a publicly held biopharmaceutical company, from 2016 to 2018. Mr. Walbert was previously a member of the board of directors of the Biotechnology Innovation Organization, the Pharmaceutical Research and Manufacturing Association, the Illinois Biotechnology Innovation Organization and World Business Chicago. Mr. Walbert earned his B.A. in Business from Muhlenberg College.
Timothy P. Walbert,自2010年公司成立起任公司的董事会主席,总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月,他是IDM Pharma, Inc.的总裁、董事兼首席执行官;公司是一家生物制药公司,于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月,他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月,他是Immunology的区域副总裁兼总经理,在此他领导HUMIRA的全球发展——于2013年超过110亿美元;且是Abbott全球心血管战略执行副总裁,该组织是一家医疗保健公司,现为AbbVie。1998年4月至2001年6月,他是Celebrex North America的董事,以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年,他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation (纳斯达克: XOMA) 、Raptor Pharmaceutical Corp. (纳斯达克: RPTP)、Egalet Corporation (纳斯达克: EGLT)、生物技术工业组织 (BIO)、伊利诺斯州生物技术工业组织 (iBIO)、 ChicagoNEXT、 a World Business Chicago (WBC) led council of technology leaders ,以及芝加哥关节炎基金会(the Greater Chicago Arthritis Foundation)的董事会任职。2013年,他被任命为 伊利诺斯州创新委员会(the Illinois Innovation Council)的主管人员。
Timothy P. Walbert has served as Chairman of Latigo Biotherapeutics, Inc.'s board of directors since October 2024. Since October 2023, Mr. Walbert has served as a senior advisor to Amgen Inc., a publicly held biotechnology company. Previously, Mr. Walbert was Chairman, President and Chief Executive Officer of Horizon Therapeutics Public Ltd Co (Horizon), a biotechnology company (acquired by Amgen), from June 2008 to October 2023. Prior to Horizon, he served as President, Chief Executive Officer and a member of the board of directors of IDM Pharma Inc., a biotechnology company (acquired by Takeda Pharmaceuticals). Prior to that, Mr. Walbert served as Executive Vice President, Commercial Operations at NeoPharm Inc., a publicly held biotechnology company. Mr. Walbert has served on the board of directors of multiple publicly held biotechnology companies, including Century Therapeutics, Inc. since September 2022, Mirum Pharmaceuticals, Inc. since April 2023, Sagimet Biosciences Inc. since March 2024, and BioMarin Pharmaceutical Inc. since February 2025, as well as Cour Pharmaceuticals Development Co., Inc. since June 2024, Odyssey Therapeutics, Inc. since October 2024, and Catalent, Inc. since February 2025 and Crystalys Therapeutics, Inc. since February 2026. He previously served on the board of directors of Aurinia Pharmaceuticals Inc., a publicly held pharmaceutical company, from 2020 to 2022, Exicure, Inc., a publicly held biotechnology company, from 2019 to 2022, Assertio Holdings, Inc., a publicly held biopharma company, from 2014 to 2020, Raptor Pharmaceutical Corp., a publicly held biotechnology company, from 2010 to 2014, XOMA Corporation, a publicly held biotechnology company, from 2011 to 2017, and Sucampo Pharmaceuticals Inc., a publicly held biopharmaceutical company, from 2016 to 2018. Mr. Walbert was previously a member of the board of directors of the Biotechnology Innovation Organization, the Pharmaceutical Research and Manufacturing Association, the Illinois Biotechnology Innovation Organization and World Business Chicago. Mr. Walbert earned his B.A. in Business from Muhlenberg College.

高管简历

中英对照 |  中文 |  英文
Jolie M. Siegel

朱莉·西格尔(Jolie M.Siegel)自2020年7月起担任我们的首席法律官。2020年6月,Siegel女士担任我们的临时首席法律官。Siegel女士于2018年8月至2020年5月担任NeonTherapeutics,Inc.的Vice President,总法律顾问兼秘书,随后被免疫肿瘤公司BioNTech SE(纳斯达克股票代码:BNTX,2020年5月)收购,在那里她负责法律,知识产权和公司合规事务。Siegel女士还在2018年3月至8月期间为Neon提供咨询法律服务。2013年2月至2017年4月,Siegel女士担任IntralinksHoldings,Inc.(NYSE:IL,后于2017年1月被SynchronossTechnologies,Inc.(NASDAQ:SNCR)收购)的高级副总裁,副总法律顾问兼助理秘书,该公司是全球金融和资本市场社区的技术提供商。担任该职位时,Siegel女士负责公司治理、合规、上市公司报告、并购、营销和财务事务。从2007年到2013年,她曾担任Choate,Hall&Stewart公司(律师事务所)的合伙人,在那里她曾从事公司交易、证券和一般商业事务,专注于私人股本、风险投资和高增长公司。从2005年到2007年,Siegel女士是Choate的合伙人,从2001年到2005年,Siegel女士是Testa,Hurwitz&Thibeault,LLP的合伙人,在那里她是业务实践小组的成员。Siegel女士拥有宾夕法尼亚大学法学院(University of Pennsylvania Law School)的法学博士学位和宾夕法尼亚大学(University of Pennsylvania)的政治学学士学位。


Jolie M. Siegel has served as Odyssey Therapeutics, Inc.'s Executive Vice President and General Counsel since January 2026 and as Secretary since February 2026. Ms. Siegel is an accomplished legal and business executive with significant experience working with biotechnology companies during periods of growth and transformation. Prior to joining Odyssey, from July 2020 to January 2026, Ms. Siegel served as Chief Legal Officer and Corporate Secretary of C4 Therapeutics, Inc. (Nasdaq: CCCC), where she also served as Secretary from February 2021 to January 2026, and as interim Chief Legal Officer in a consulting capacity in June 2020. From August 2018 to May 2020, Ms. Siegel served as Vice President, General Counsel and Corporate Secretary of Neon Therapeutics, Inc., an immune oncology company. Ms. Siegel also provided consulting legal services to Neon between March and August 2018. At each of C4 Therapeutics and Neon Therapeutics, Ms. Siegel was responsible for legal, intellectual property and corporate compliance matters. From February 2013 to April 2017, Ms. Siegel served as Senior Vice President, Deputy General Counsel and Assistant Secretary of Intralinks Holdings, Inc., a technology provider for the global financial and capital markets communities. In this role, Ms. Siegel was responsible for corporate governance, compliance, public company reporting, mergers and acquisition, marketing and finance matters. From 2007 to 2013, Ms. Siegel was a partner at Choate, Hall & Stewart LLP, a law firm, where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high growth companies. Ms. Siegel holds a J.D. from the University of Pennsylvania Law School and a B.A. in political science from the University of Pennsylvania.
朱莉·西格尔(Jolie M.Siegel)自2020年7月起担任我们的首席法律官。2020年6月,Siegel女士担任我们的临时首席法律官。Siegel女士于2018年8月至2020年5月担任NeonTherapeutics,Inc.的Vice President,总法律顾问兼秘书,随后被免疫肿瘤公司BioNTech SE(纳斯达克股票代码:BNTX,2020年5月)收购,在那里她负责法律,知识产权和公司合规事务。Siegel女士还在2018年3月至8月期间为Neon提供咨询法律服务。2013年2月至2017年4月,Siegel女士担任IntralinksHoldings,Inc.(NYSE:IL,后于2017年1月被SynchronossTechnologies,Inc.(NASDAQ:SNCR)收购)的高级副总裁,副总法律顾问兼助理秘书,该公司是全球金融和资本市场社区的技术提供商。担任该职位时,Siegel女士负责公司治理、合规、上市公司报告、并购、营销和财务事务。从2007年到2013年,她曾担任Choate,Hall&Stewart公司(律师事务所)的合伙人,在那里她曾从事公司交易、证券和一般商业事务,专注于私人股本、风险投资和高增长公司。从2005年到2007年,Siegel女士是Choate的合伙人,从2001年到2005年,Siegel女士是Testa,Hurwitz&Thibeault,LLP的合伙人,在那里她是业务实践小组的成员。Siegel女士拥有宾夕法尼亚大学法学院(University of Pennsylvania Law School)的法学博士学位和宾夕法尼亚大学(University of Pennsylvania)的政治学学士学位。
Jolie M. Siegel has served as Odyssey Therapeutics, Inc.'s Executive Vice President and General Counsel since January 2026 and as Secretary since February 2026. Ms. Siegel is an accomplished legal and business executive with significant experience working with biotechnology companies during periods of growth and transformation. Prior to joining Odyssey, from July 2020 to January 2026, Ms. Siegel served as Chief Legal Officer and Corporate Secretary of C4 Therapeutics, Inc. (Nasdaq: CCCC), where she also served as Secretary from February 2021 to January 2026, and as interim Chief Legal Officer in a consulting capacity in June 2020. From August 2018 to May 2020, Ms. Siegel served as Vice President, General Counsel and Corporate Secretary of Neon Therapeutics, Inc., an immune oncology company. Ms. Siegel also provided consulting legal services to Neon between March and August 2018. At each of C4 Therapeutics and Neon Therapeutics, Ms. Siegel was responsible for legal, intellectual property and corporate compliance matters. From February 2013 to April 2017, Ms. Siegel served as Senior Vice President, Deputy General Counsel and Assistant Secretary of Intralinks Holdings, Inc., a technology provider for the global financial and capital markets communities. In this role, Ms. Siegel was responsible for corporate governance, compliance, public company reporting, mergers and acquisition, marketing and finance matters. From 2007 to 2013, Ms. Siegel was a partner at Choate, Hall & Stewart LLP, a law firm, where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high growth companies. Ms. Siegel holds a J.D. from the University of Pennsylvania Law School and a B.A. in political science from the University of Pennsylvania.
Gary D. Glick

Gary D. Glick,是一位化学家和连续生物技术企业家,在生物技术行业拥有超过15年的经验。他创立了几家成功的公司,包括IFM Therapeutics,LLC,即私营生物技术公司IFM。Glick博士自2019年12月起担任IFM执行主席,此前曾于2015年至2019年11月担任首席执行官。在Glick博士担任首席执行官期间,IFM推进了从构思到临床开发的三个项目,并执行了几项重大交易,迄今已产生7.5亿美元的收益。在实现各种里程碑的情况下,此类销售的收益可能会达到47亿美元以上。在2021年创立Odyssey之前,Glick博士于2020年2月与他人共同创立并推出了Scorpion Therapeutics,即Scorpion,在该公司的构想和建设中发挥了重要作用。在2020年2月至2021年2月担任首席执行官期间,Scorpion的员工人数增长至近50人,并通过两次融资筹集了2.7亿美元。2025年1月13日,公告称礼来与公司签订了一项最终协议,将以高达25亿美元的现金收购Scorpion。Glick博士还在其职业生涯早期创立了Lycera公司,担任首席科学官。格利克博士在哥伦比亚大学获得有机化学博士学位,并在哈佛大学完成了美国国立卫生研究院有机化学博士后研究金。


Gary D. Glick is Odyssey Therapeutics, Inc.'s founder and has served as Odyssey Therapeutics, Inc.'s President, Chief Executive Officer and a director since April 2021. Dr. Glick is a chemist and serial biotechnology entrepreneur with over 15 years of experience in the biotechnology industry. Dr. Glick has also served as the Executive Chairman of Charm Therapeutics Limited, or Charm, a London based biotechnology company focused on developing a new generation of menin inhibitors for acute myeloid leukemia, since January 2022, and as interim Chief Executive Officer since June 2025. While Dr. Glick works on a full time basis for Odyssey as Odyssey Therapeutics, Inc.'s Chief Executive Officer, he also devotes approximately 10 hours per week, on average, to his role at Charm, which time commitment is not materially different to what was required when he was Executive Chairman and not also interim Chief Executive Officer. In fulfilling his responsibilities to Charm, Dr. Glick seeks to leverage the time zone difference between London and Boston to complete as many of his responsibilities as possible for Charm during times that are outside of customary business hours in Boston. Dr. Glick has founded several successful companies, including IFM Therapeutics, LLC, or IFM, a private biotechnology company. Dr. Glick has served as Executive Chairman of IFM since December 2019 and previously served as Chief Executive Officer from 2015 to November 2019. During Dr. Glick's tenure as Chief Executive Officer, IFM progressed three programs from ideation to clinical development and executed several major transactions generating proceeds to date of $750 million. Subject to the achievement of various milestones, proceeds from those sales could reach more than $4.7 billion. Prior to founding Odyssey in 2021, Dr. Glick co founded and launched Scorpion Therapeutics, or Scorpion, in February 2020, where he played an instrumental role in the conception and building of the company. During his tenure as Chief Executive Officer from February 2020 to February 2021, Scorpion grew to nearly 50 employees and raised $270 million across two financings. In 2025, Eli Lilly and Company acquired Scorpion for up to $2.5 billion in cash. Dr. Glick also founded Lycera Corporation earlier in his career, serving as Chief Scientific Officer. Dr. Glick received his Ph.D. in organic chemistry from Columbia University and completed an NIH postdoctoral fellowship in organic chemistry at Harvard University.
Gary D. Glick,是一位化学家和连续生物技术企业家,在生物技术行业拥有超过15年的经验。他创立了几家成功的公司,包括IFM Therapeutics,LLC,即私营生物技术公司IFM。Glick博士自2019年12月起担任IFM执行主席,此前曾于2015年至2019年11月担任首席执行官。在Glick博士担任首席执行官期间,IFM推进了从构思到临床开发的三个项目,并执行了几项重大交易,迄今已产生7.5亿美元的收益。在实现各种里程碑的情况下,此类销售的收益可能会达到47亿美元以上。在2021年创立Odyssey之前,Glick博士于2020年2月与他人共同创立并推出了Scorpion Therapeutics,即Scorpion,在该公司的构想和建设中发挥了重要作用。在2020年2月至2021年2月担任首席执行官期间,Scorpion的员工人数增长至近50人,并通过两次融资筹集了2.7亿美元。2025年1月13日,公告称礼来与公司签订了一项最终协议,将以高达25亿美元的现金收购Scorpion。Glick博士还在其职业生涯早期创立了Lycera公司,担任首席科学官。格利克博士在哥伦比亚大学获得有机化学博士学位,并在哈佛大学完成了美国国立卫生研究院有机化学博士后研究金。
Gary D. Glick is Odyssey Therapeutics, Inc.'s founder and has served as Odyssey Therapeutics, Inc.'s President, Chief Executive Officer and a director since April 2021. Dr. Glick is a chemist and serial biotechnology entrepreneur with over 15 years of experience in the biotechnology industry. Dr. Glick has also served as the Executive Chairman of Charm Therapeutics Limited, or Charm, a London based biotechnology company focused on developing a new generation of menin inhibitors for acute myeloid leukemia, since January 2022, and as interim Chief Executive Officer since June 2025. While Dr. Glick works on a full time basis for Odyssey as Odyssey Therapeutics, Inc.'s Chief Executive Officer, he also devotes approximately 10 hours per week, on average, to his role at Charm, which time commitment is not materially different to what was required when he was Executive Chairman and not also interim Chief Executive Officer. In fulfilling his responsibilities to Charm, Dr. Glick seeks to leverage the time zone difference between London and Boston to complete as many of his responsibilities as possible for Charm during times that are outside of customary business hours in Boston. Dr. Glick has founded several successful companies, including IFM Therapeutics, LLC, or IFM, a private biotechnology company. Dr. Glick has served as Executive Chairman of IFM since December 2019 and previously served as Chief Executive Officer from 2015 to November 2019. During Dr. Glick's tenure as Chief Executive Officer, IFM progressed three programs from ideation to clinical development and executed several major transactions generating proceeds to date of $750 million. Subject to the achievement of various milestones, proceeds from those sales could reach more than $4.7 billion. Prior to founding Odyssey in 2021, Dr. Glick co founded and launched Scorpion Therapeutics, or Scorpion, in February 2020, where he played an instrumental role in the conception and building of the company. During his tenure as Chief Executive Officer from February 2020 to February 2021, Scorpion grew to nearly 50 employees and raised $270 million across two financings. In 2025, Eli Lilly and Company acquired Scorpion for up to $2.5 billion in cash. Dr. Glick also founded Lycera Corporation earlier in his career, serving as Chief Scientific Officer. Dr. Glick received his Ph.D. in organic chemistry from Columbia University and completed an NIH postdoctoral fellowship in organic chemistry at Harvard University.
Jason Haas

Jason Haas,是一位充满活力的商业领袖,在医疗保健投资银行和生物技术行业拥有超过25年的经验。在加入奥德赛之前,他于2021年10月至2024年11月期间在Syros Pharmaceuticals, Inc.(SYRS)担任首席财务官。此前,Haas先生于2016年6月至2021年10月在巴克莱银行 PLC担任美洲医疗保健投资银行业务联席主管。2012年至2016年6月,Haas先生在德意志银行 AG或德意志银行担任美洲医疗保健投资银行业务主管。在此之前,他是高盛 Sachs & Co. LLC医疗保健投资银行团队的董事总经理。Haas先生目前在一家上市生物技术公司Ligand Pharmaceuticals Incorporated(纳斯达克:LGND)的董事会任职。哈斯先生在高露洁大学获得国际关系和经济学学士学位,在哥伦比亚商学院获得工商管理硕士学位。


Jason Haas has served as Odyssey Therapeutics, Inc.'s Chief Financial Officer since December 2024. Mr. Haas is a dynamic business leader with over 25 years of experience in healthcare investment banking and the biotechnology industry. Prior to joining Odyssey, he served as Chief Financial Officer at Syros Pharmaceuticals, Inc. (Nasdaq: SYRS) from October 2021 until November 2024. Previously, Mr. Haas served as Co head of Americas, Healthcare Investment Banking at Barclays plc from June 2016 to October 2021. From 2012 to June 2016, Mr. Haas served as Head of Americas, Healthcare Investment Banking at Deutsche Bank AG, or Deutsche Bank. Before that, he was a Managing Director on the Healthcare Investment Banking team at Goldman Sachs & Co. Mr. Haas currently serves on the board of directors of Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a public biotechnology company. Mr. Haas earned his B.A. in international relations and economics from Colgate University and his M.B.A. from Columbia Business School.
Jason Haas,是一位充满活力的商业领袖,在医疗保健投资银行和生物技术行业拥有超过25年的经验。在加入奥德赛之前,他于2021年10月至2024年11月期间在Syros Pharmaceuticals, Inc.(SYRS)担任首席财务官。此前,Haas先生于2016年6月至2021年10月在巴克莱银行 PLC担任美洲医疗保健投资银行业务联席主管。2012年至2016年6月,Haas先生在德意志银行 AG或德意志银行担任美洲医疗保健投资银行业务主管。在此之前,他是高盛 Sachs & Co. LLC医疗保健投资银行团队的董事总经理。Haas先生目前在一家上市生物技术公司Ligand Pharmaceuticals Incorporated(纳斯达克:LGND)的董事会任职。哈斯先生在高露洁大学获得国际关系和经济学学士学位,在哥伦比亚商学院获得工商管理硕士学位。
Jason Haas has served as Odyssey Therapeutics, Inc.'s Chief Financial Officer since December 2024. Mr. Haas is a dynamic business leader with over 25 years of experience in healthcare investment banking and the biotechnology industry. Prior to joining Odyssey, he served as Chief Financial Officer at Syros Pharmaceuticals, Inc. (Nasdaq: SYRS) from October 2021 until November 2024. Previously, Mr. Haas served as Co head of Americas, Healthcare Investment Banking at Barclays plc from June 2016 to October 2021. From 2012 to June 2016, Mr. Haas served as Head of Americas, Healthcare Investment Banking at Deutsche Bank AG, or Deutsche Bank. Before that, he was a Managing Director on the Healthcare Investment Banking team at Goldman Sachs & Co. Mr. Haas currently serves on the board of directors of Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a public biotechnology company. Mr. Haas earned his B.A. in international relations and economics from Colgate University and his M.B.A. from Columbia Business School.
Collin Todd

Collin Todd,自2021年12月加入Odyssey以来,Todd先生负责监督Odyssey Therapeutics,Inc.的B轮和C轮融资以及Odyssey Therapeutics,Inc.合作协议的执行,包括与强生和辉瑞的合作协议。Todd先生在生物技术行业的投资、公司运营、企业和业务发展以及战略规划方面拥有超过十年的经验。从2017年9月到2021年12月,Todd先生在SpringWorks Therapeutics,Inc.担任过各种战略和业务发展职务,参与完成了超过6亿美元的私人和公共融资,并执行了10多项许可和合作交易。在加入SpringWorks之前,Todd先生是Moderna公司的策略专业人士,也是OrbiMed Advisors LLC(OrbiMed)私募股权团队的成员,在那里他参与了交易采购、评估和执行。Todd先生的职业生涯始于美银美林的投资银行家,在那里他曾与跨咨询、融资和并购的医疗保健公司合作。Todd先生目前担任CTRL Therapeutics的董事会成员。托德先生在加州大学洛杉矶分校获得经济学学士学位。


Collin Todd has served as Odyssey Therapeutics, Inc.'s Senior Vice President, Strategy and Business Development since June 2024 and is responsible for the management of Odyssey Therapeutics, Inc.'s strategic, business development and capital formation matters. Since joining Odyssey in December 2021, Mr. Todd has overseen Odyssey Therapeutics, Inc.'s Series B, Series C and Series D financings and the execution of Odyssey Therapeutics, Inc.'s collaboration agreements. Mr. Todd has over a decade of experience in investing, company operations, corporate and business development and strategic planning in the biotechnology industry. From September 2017 until December 2021, Mr. Todd served in various strategy and business development roles at SpringWorks Therapeutics, Inc., where he was involved in completing over $600 million of private and public financings and the execution of more than 10 licensing and partnering transactions. Prior to SpringWorks, Mr. Todd was a strategy professional at Moderna, Inc. and a member of the private equity team at OrbiMed Advisors LLC, or OrbiMed, where he was involved in deal sourcing, evaluation and execution. Mr. Todd began his career as an investment banker at Bank of America Merrill Lynch where he worked with healthcare companies across advisory, capital raising and M&A. Mr. Todd currently serves on the board of directors of cTRL Therapeutics. Mr. Todd earned his B.A. in economics at the University of California, Los Angeles.
Collin Todd,自2021年12月加入Odyssey以来,Todd先生负责监督Odyssey Therapeutics,Inc.的B轮和C轮融资以及Odyssey Therapeutics,Inc.合作协议的执行,包括与强生和辉瑞的合作协议。Todd先生在生物技术行业的投资、公司运营、企业和业务发展以及战略规划方面拥有超过十年的经验。从2017年9月到2021年12月,Todd先生在SpringWorks Therapeutics,Inc.担任过各种战略和业务发展职务,参与完成了超过6亿美元的私人和公共融资,并执行了10多项许可和合作交易。在加入SpringWorks之前,Todd先生是Moderna公司的策略专业人士,也是OrbiMed Advisors LLC(OrbiMed)私募股权团队的成员,在那里他参与了交易采购、评估和执行。Todd先生的职业生涯始于美银美林的投资银行家,在那里他曾与跨咨询、融资和并购的医疗保健公司合作。Todd先生目前担任CTRL Therapeutics的董事会成员。托德先生在加州大学洛杉矶分校获得经济学学士学位。
Collin Todd has served as Odyssey Therapeutics, Inc.'s Senior Vice President, Strategy and Business Development since June 2024 and is responsible for the management of Odyssey Therapeutics, Inc.'s strategic, business development and capital formation matters. Since joining Odyssey in December 2021, Mr. Todd has overseen Odyssey Therapeutics, Inc.'s Series B, Series C and Series D financings and the execution of Odyssey Therapeutics, Inc.'s collaboration agreements. Mr. Todd has over a decade of experience in investing, company operations, corporate and business development and strategic planning in the biotechnology industry. From September 2017 until December 2021, Mr. Todd served in various strategy and business development roles at SpringWorks Therapeutics, Inc., where he was involved in completing over $600 million of private and public financings and the execution of more than 10 licensing and partnering transactions. Prior to SpringWorks, Mr. Todd was a strategy professional at Moderna, Inc. and a member of the private equity team at OrbiMed Advisors LLC, or OrbiMed, where he was involved in deal sourcing, evaluation and execution. Mr. Todd began his career as an investment banker at Bank of America Merrill Lynch where he worked with healthcare companies across advisory, capital raising and M&A. Mr. Todd currently serves on the board of directors of cTRL Therapeutics. Mr. Todd earned his B.A. in economics at the University of California, Los Angeles.
Natalie Dales

Natalie Dales自2022年11月起担任Odyssey Therapeutics,Inc.的研究运营和投资组合战略主管。Dales博士还曾在Odyssey Therapeutics,Inc.的Enabling Sciences部门担任多个资历不断增加的职务,包括2021年10月至2022年2月担任高级副总裁,2022年2月至2022年11月担任执行副总裁。Dales博士是一位成就卓著的科学家,在小分子药物发现方面拥有20多年的经验,在她的整个职业生涯中一直领导和指导生物制药和生物技术行业的团队。在加入奥德赛之前,戴尔斯博士曾在诺华公司(纽约证券交易所代码:NVS)工作了17年,在那里她担任过从科学研究员到全球发现化学执行董事的越来越资深的职务。此外,从2019年10月到2021年10月,戴尔斯博士还担任了全球发现化学的投资组合和战略主管。她还是诺华集团内部创新孵化器诺华Genesis Labs的高级顾问。在其职业生涯的早期,戴尔斯博士曾在Millennium Pharmaceuticals,Inc.(后被Takeda Pharmaceutical Company Limited收购,纽约证券交易所代码:TAK)担任高级科学家,在那里她为肿瘤学、心血管和新陈代谢研究项目做出了贡献。戴尔斯博士在威斯康星大学获得有机化学博士学位,并在密歇根大学获得化学学士学位。


Natalie Dales has served as Odyssey Therapeutics, Inc.'s Chief of Research Operations and Portfolio Strategy since November 2022. Dr. Dales also served in several roles of increasing seniority within Odyssey Therapeutics, Inc.'s Enabling Sciences department, including as Senior Vice President from October 2021 to February 2022 and Executive Vice President from February 2022 to November 2022. Dr. Dales is an accomplished scientist with more than 20 years of experience in small molecule drug discovery and has led and mentored teams across the biopharmaceutical and biotechnology industries throughout her career. Prior to joining Odyssey, Dr. Dales worked at Novartis AG (NYSE: NVS) for 17 years, where she held roles of increasing seniority from Scientific Investigator to Executive Director, Global Discovery Chemistry. Additionally, from October 2019 to October 2021, Dr. Dales also held the role of Head of Portfolio and Strategy for Global Discovery Chemistry. She was also a Senior Advisor to Novartis Genesis Labs, Novartis AG's internal innovation incubator. Earlier in her career, Dr. Dales worked as a senior scientist at Millennium Pharmaceuticals, Inc. (later acquired by Takeda Pharmaceutical Company Limited, NYSE: TAK), where she contributed to oncology, cardiovascular and metabolism research programs. Dr. Dales received her Ph.D. in organic chemistry from the University of Wisconsin and earned her B.S. in chemistry from the University of Michigan.
Natalie Dales自2022年11月起担任Odyssey Therapeutics,Inc.的研究运营和投资组合战略主管。Dales博士还曾在Odyssey Therapeutics,Inc.的Enabling Sciences部门担任多个资历不断增加的职务,包括2021年10月至2022年2月担任高级副总裁,2022年2月至2022年11月担任执行副总裁。Dales博士是一位成就卓著的科学家,在小分子药物发现方面拥有20多年的经验,在她的整个职业生涯中一直领导和指导生物制药和生物技术行业的团队。在加入奥德赛之前,戴尔斯博士曾在诺华公司(纽约证券交易所代码:NVS)工作了17年,在那里她担任过从科学研究员到全球发现化学执行董事的越来越资深的职务。此外,从2019年10月到2021年10月,戴尔斯博士还担任了全球发现化学的投资组合和战略主管。她还是诺华集团内部创新孵化器诺华Genesis Labs的高级顾问。在其职业生涯的早期,戴尔斯博士曾在Millennium Pharmaceuticals,Inc.(后被Takeda Pharmaceutical Company Limited收购,纽约证券交易所代码:TAK)担任高级科学家,在那里她为肿瘤学、心血管和新陈代谢研究项目做出了贡献。戴尔斯博士在威斯康星大学获得有机化学博士学位,并在密歇根大学获得化学学士学位。
Natalie Dales has served as Odyssey Therapeutics, Inc.'s Chief of Research Operations and Portfolio Strategy since November 2022. Dr. Dales also served in several roles of increasing seniority within Odyssey Therapeutics, Inc.'s Enabling Sciences department, including as Senior Vice President from October 2021 to February 2022 and Executive Vice President from February 2022 to November 2022. Dr. Dales is an accomplished scientist with more than 20 years of experience in small molecule drug discovery and has led and mentored teams across the biopharmaceutical and biotechnology industries throughout her career. Prior to joining Odyssey, Dr. Dales worked at Novartis AG (NYSE: NVS) for 17 years, where she held roles of increasing seniority from Scientific Investigator to Executive Director, Global Discovery Chemistry. Additionally, from October 2019 to October 2021, Dr. Dales also held the role of Head of Portfolio and Strategy for Global Discovery Chemistry. She was also a Senior Advisor to Novartis Genesis Labs, Novartis AG's internal innovation incubator. Earlier in her career, Dr. Dales worked as a senior scientist at Millennium Pharmaceuticals, Inc. (later acquired by Takeda Pharmaceutical Company Limited, NYSE: TAK), where she contributed to oncology, cardiovascular and metabolism research programs. Dr. Dales received her Ph.D. in organic chemistry from the University of Wisconsin and earned her B.S. in chemistry from the University of Michigan.
Anthony Opipari

Anthony Opipari自2024年8月起担任Odyssey Therapeutics,Inc.的临时首席医疗官。Opipari博士自公司成立以来一直在Odyssey领导转化医学,并于2021年加入担任转化医学高级副总裁。他于2024年被任命为执行副总裁。Opipari博士是一名内科科学家,曾作为临床医生和首席研究员在学术医学领域拥有经验,并共同创立了多家生物技术公司。在加入奥德赛之前,他于2006年共同创立了Lycera公司,并在那里担任生物学高级总监,直到2021年。2021年,他共同创立了Firstwave Bio和IFM Therapeutics。他领导了转化医学的研究,并在Firstwave和IFM指导早期临床开发,直到2021年加入奥德赛。在进入该行业之前,他是密歇根大学医学院教师的成员,在妇科肿瘤科任职。Opipari博士获得了细胞和分子生物学的医学博士和博士学位,并在密歇根大学完成了研究生医学培训。


Anthony Opipari has served as Odyssey Therapeutics, Inc.'s interim Chief Medical Officer since August 2024. Dr. Opipari has led translational medicine at Odyssey since the company was founded having joined as a Senior Vice President, Translational Medicine in 2021. He was appointed as an Executive Vice President in 2024. Dr. Opipari is a physician scientist with experience in academic medicine as a clinician and principal investigator as well as co founding several biotechnology companies. Before joining Odyssey, he co founded Lycera Corporation in 2006 and worked there as a Senior Director of Biology until 2021. In 2021 he co founded both Firstwave Bio and IFM Therapeutics. He led research in translational medicine and directed early clinical development at both Firstwave and IFM until joining Odyssey in 2021. Prior to working in the industry, he was a member of the University of Michigan Medical School faculty with an appointment in the Division of Gynecological Oncology. Dr. Opipari received his M.D. and Ph.D. in cellular and molecular biology and completed his post graduate medical training at the University of Michigan.
Anthony Opipari自2024年8月起担任Odyssey Therapeutics,Inc.的临时首席医疗官。Opipari博士自公司成立以来一直在Odyssey领导转化医学,并于2021年加入担任转化医学高级副总裁。他于2024年被任命为执行副总裁。Opipari博士是一名内科科学家,曾作为临床医生和首席研究员在学术医学领域拥有经验,并共同创立了多家生物技术公司。在加入奥德赛之前,他于2006年共同创立了Lycera公司,并在那里担任生物学高级总监,直到2021年。2021年,他共同创立了Firstwave Bio和IFM Therapeutics。他领导了转化医学的研究,并在Firstwave和IFM指导早期临床开发,直到2021年加入奥德赛。在进入该行业之前,他是密歇根大学医学院教师的成员,在妇科肿瘤科任职。Opipari博士获得了细胞和分子生物学的医学博士和博士学位,并在密歇根大学完成了研究生医学培训。
Anthony Opipari has served as Odyssey Therapeutics, Inc.'s interim Chief Medical Officer since August 2024. Dr. Opipari has led translational medicine at Odyssey since the company was founded having joined as a Senior Vice President, Translational Medicine in 2021. He was appointed as an Executive Vice President in 2024. Dr. Opipari is a physician scientist with experience in academic medicine as a clinician and principal investigator as well as co founding several biotechnology companies. Before joining Odyssey, he co founded Lycera Corporation in 2006 and worked there as a Senior Director of Biology until 2021. In 2021 he co founded both Firstwave Bio and IFM Therapeutics. He led research in translational medicine and directed early clinical development at both Firstwave and IFM until joining Odyssey in 2021. Prior to working in the industry, he was a member of the University of Michigan Medical School faculty with an appointment in the Division of Gynecological Oncology. Dr. Opipari received his M.D. and Ph.D. in cellular and molecular biology and completed his post graduate medical training at the University of Michigan.